HMGCR and inherited lipid metabolism disorder: Key limitations include: (1) estimation of on‐target effects of drug use only (these models do not estimate potential off‐target effects); (2) lack of precision to robustly identify modest but potentially meaningful effects for some targets, including HMGCR inhibition; and (3) the possibility of survival bias, given that dyslipidaemias increase mortality prior to late‐onset PD, which might bias findings toward spurious inverse associations with PD risk.